NDC Active Ingredient Denosumab

Active Ingredient Information

What is Denosumab?

A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.

What is the usage for Denosumab?

Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

How many products in the NDC database contain Denosumab?

The NDC database has 2 products with the active ingredient Denosumab. The following table lists all the products that have this active ingredient.

NDC Products with Denosumab

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
55513-710Proprietary Name: Prolia DenosumabInjectionSubcutaneousAmgen IncACTIVE
55513-730Proprietary Name: Xgeva DenosumabInjectionSubcutaneousAmgen IncACTIVE